Form 4: Disc Medicine Director Mona Ashiya Reports Indirect Stock Purchases

Director Mona Ashiya reports indirect purchases of Disc Medicine (IRON) common stock through affiliated entities.

Summary

• On June 17, 2024, Mona Ashiya, a director of Disc Medicine, Inc. (IRON), reported indirect purchases of common stock.
• The purchases were made through affiliated entities: OrbiMed Private Investments VI, LP (OPI VI), OrbiMed Private Investments VIII, LP (OPI VIII), and OrbiMed Genesis Master Fund, L.P. (Genesis).
• A total of 28,404 shares were purchased at $36 per share through OPI VI, 43,944 shares were purchased at $36 per share through OPI VIII, and 10,986 shares were purchased at $36 per share through Genesis.
• Following these transactions, the total number of shares beneficially owned indirectly by these entities are 608,611, 941,569, and 235,391 respectively.
• Ashiya disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a report of stock purchases by a director through affiliated entities, which doesn't inherently indicate positive or negative sentiment.

Positives

• Director's indirect stock purchases may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding 10% or more of a company's shares) buy or sell their company's stock. These filings provide transparency into insider transactions.

Stakeholder Impact

• The stock purchases could be viewed positively by shareholders as it may indicate confidence from a director in the company's prospects.

Key Dates